As we see it, sales through the core direct selling segment decreased nearly 13%, though with the acquisition of Hiya Health, we estimate that total sales in the June quarter were up 5.8% year over year to $225.2 million. Factoring in some operating margin compression, we estimate that adjusted EPS of $0.54 matched the year-earlier total. In our view, the company's core direct selling business will start to stabilize in 2H:25 and grow in 2026. Along with our assumption of strong results from Hiya and operating margin expansion next year, we maintain our adjusted 2025 and 2026 EPS estimates of $2.61 and $3.39, respectively, up from $2.59 in 2024. We maintain our $61 price target, which is based on 18x our 2026 EPS forecast of $3.39. We assign our moderate risk rating given the company's solid balance sheet, healthy free cash flow and estimated earnings recovery.